Summary of Conference Call Records Company and Industry Overview - **Companies Involved**: 新宙邦 (Xinjubang) and 阿科力 (Acoly) - **Industry**: New materials, specifically focusing on lithium battery materials, organic fluorine chemicals, and cooling technologies for data centers Key Points and Arguments Xinjubang's Business and Market Position - Xinjubang has a comprehensive industrial layout with 10 production bases globally by the end of 2024, including 9 in China and 1 in Europe, enhancing customer service and loyalty [2][5] - The company benefits from the growth in the new energy storage, automotive, and AI industries, with lithium battery materials expected to see both volume and price increases [2][5] - Current prices for new energy materials are at historical lows, with lithium hexafluorophosphate prices dropping significantly from 600,000 RMB/ton in 2021 to around 50,000-60,000 RMB/ton now [6] - Domestic apparent consumption of lithium hexafluorophosphate is projected to grow over 30% year-on-year in 2024, with further growth of 20%-30% expected in 2025 due to the development of new energy vehicles [2][6] Organic Fluorine Chemicals Market - The organic fluorine chemicals market is seen as a golden industry, with applications in pharmaceuticals, pesticides, and semiconductors [7] - Xinjubang aims to expand its market share as 3M plans to exit the market, which will create opportunities for domestic companies [7][11] Liquid Cooling Technology - Liquid cooling technology is emerging as a preferred solution for data centers, especially with the rise of AI, which increases cooling demands [9][10] - Immersion cooling is highlighted for its superior heat dissipation efficiency, making it suitable for high-power single-cabinet data centers [10] Acoly's Business Transformation - Acoly is transitioning from its original polyether amine business to focus on the development of cyclic olefin copolymer (COC) materials, which are crucial for optical lenses and pharmaceutical packaging [4][16] - Acoly plans to establish a 10,000-ton COC production facility by the end of 2026, with an additional 20,000-ton expansion planned for 2027 [4][18] - The company has already secured small orders for pharmaceutical packaging, indicating market interest and potential for growth [18][19] Competitive Landscape and Future Outlook - The COC market is characterized by high production difficulty, with only a few companies globally capable of producing it, giving Acoly a competitive edge [17][20] - Acoly is optimistic about its future growth potential, with expectations of significant market share and valuation increases due to successful technology breakthroughs [20] Financial Projections - Xinjubang is projected to achieve a compound annual growth rate (CAGR) of over 20%, potentially reaching 30% by 2026, driven by the demand for its products in the AI and new energy sectors [12] Additional Important Insights - The exit of 3M from the PFAS market, which generates approximately $1.3 billion annually, is expected to benefit domestic companies like Xinjubang and Acoly [11][12] - The overall new energy industry is currently facing challenges with overcapacity and slight losses, but improvements in supply dynamics are anticipated by 2026 [15]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index in the next six months [4][10][18]. Core Views - The report highlights that the polyether amine industry is currently at a low point, with the company's performance under short-term pressure. However, there is optimism regarding the gradual ramp-up of COC (Cyclic Olefin Copolymer) products in the future [2][9][10]. - The company is actively exploring niche markets and has made progress in its COC production line, which has entered formal production, potentially opening a second growth curve for the company [9][10]. Financial Summary - **Revenue Projections**: The company is expected to generate revenues of 6.08 billion, 11.26 billion, and 16.31 billion yuan from 2025 to 2027, with year-on-year growth rates of 30.3%, 85.3%, and 44.8% respectively [10]. - **Net Profit Projections**: The projected net profits for the same period are 0.17 billion, 1.17 billion, and 2.70 billion yuan, with significant year-on-year growth rates of 185.9%, 593.0%, and 130.5% [10]. - **Earnings Per Share (EPS)**: The EPS is expected to be 0.18, 1.22, and 2.82 yuan for 2025, 2026, and 2027 respectively [10]. - **Price-to-Earnings (P/E) Ratio**: The P/E ratios are projected to be 252.8, 36.5, and 15.8 for the years 2025, 2026, and 2027 respectively [10]. Industry Context - The polyether amine industry is facing intense competition, leading to a decline in both sales volume and price. The report notes that the average selling price of the company's products has decreased, while raw material costs have increased significantly [2][8]. - The company is focusing on expanding its international market presence and enhancing relationships with high-quality clients to mitigate competitive pressures [8][9].

Core Viewpoint - The article discusses the recent contract signed by Akoli with Wuxi Dacheng High-tech Materials Co., Ltd. for the sale of cyclic olefin copolymer (COC), highlighting the company's efforts to expand its market presence and the challenges it faces in the competitive landscape of the polymer industry [2][3]. Group 1: Company Developments - Akoli signed a sales contract with Wuxi Dacheng for COC, with a total transaction amount of RMB 2.6 million, to be delivered in four batches from September to December 2025 [2]. - Wuxi Dacheng is a subsidiary of Akoli, focusing on the development and production of pharmaceutical-grade COC materials [2]. - The pricing of the COC products is based on production costs and market conditions, ensuring fairness and no harm to shareholders [2]. Group 2: Market Analysis - The domestic demand for COC/COP is projected to reach 45,000 tons by 2025, with a compound annual growth rate (CAGR) of 18.9% [3]. - Akoli's revenue for the first half of 2025 was RMB 213.96 million, a decrease of 11.63% year-on-year, with a net profit attributable to shareholders of -RMB 5.31 million, down 367.84% [3][6]. - The decline in revenue and profit is attributed to decreased sales volume and prices of its main product, polyether amine, particularly in the wind power sector [3][6]. Group 3: Strategic Initiatives - In response to increased competition in the domestic wind power market, Akoli is actively exploring international markets and enhancing sales in the oil and gas sector [5]. - The company is also expanding its market share in the automotive coatings sector with optical-grade polymer materials [5]. - Akoli's production line for high-transparency materials (COC) has completed trial production and is now in formal production, with initial products being tested by downstream clients [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4][5] Core Views - The company's main business is under pressure, but the COC (Cyclic Olefin Copolymer) industrialization is expected to take off, leading to a maintained "Buy" rating [4][5] - In 2024, the company achieved revenue of 466 million yuan, a year-on-year decrease of 13.14%, and a net profit attributable to shareholders of -19.65 million yuan, indicating a shift from profit to loss [4][5] - The first quarter of 2025 saw revenue of 106 million yuan, a year-on-year increase of 2.70%, but a net profit of -4.83 million yuan, again indicating a loss [4][5] - The company is facing intense competition in its main business of polyether amine products, leading to price declines and subsequent losses [4][5] - The COC production line is expected to officially start mass production in 2025, with significant market anticipation [5][6] Financial Summary - Revenue and profit forecasts for 2025-2027 have been adjusted downwards, with expected net profits of 21 million yuan, 105 million yuan, and 254 million yuan respectively [4][8] - The corresponding EPS (Earnings Per Share) is projected to be 0.23 yuan, 1.19 yuan, and 2.89 yuan for the years 2025-2027 [4][8] - The current stock price corresponds to P/E ratios of 201.0, 39.4, and 16.2 for the years 2025-2027 [4][8] - The company has signed a strategic cooperation agreement with Poly New Energy, which is expected to positively impact future operating performance [6][8]

Group 1: Company Overview and Strategic Projects - Shaoxing Bestmay Chemical Co., Ltd. is actively expanding its product lines in the C5 chemical sector, including the "Annual Production of 8,500 Tons of Ketone Series Green New Materials Project" and the "Annual Production of 12,100 Tons of Cyclopentane Series Green New Materials Project" [1][2][3] - The company has achieved stable operation of its ketone facility, with product quality meeting standards and sales status being steady [2][3] - The company is positioned as a leader in the domestic C5 comprehensive utilization field, enhancing its product offerings and reducing reliance on imports [2][3] Group 2: Financial Performance and Growth - In 2024, the company reported a revenue of 1.328 billion RMB, representing a year-on-year growth of 89.97% due to the full-year consolidation of Ningbo Jielike's operations following an 80% stake acquisition [5][6] - The revenue from C5 series products increased from 11.67 million RMB in 2023 to 73.12 million RMB in 2024, marking a growth of 5.26 times [20] Group 3: Research and Development - The company invested 45.52 million RMB in R&D in 2024, a 13.7% increase from the previous year, and holds 58 authorized patents, including 32 invention patents [6][8] - The focus on R&D has led to the development of proprietary technologies that enhance production efficiency and reduce costs, such as low-temperature continuous nitration and solid salt recovery technologies [18] Group 4: Market Position and Competitive Advantage - The company is recognized as a national high-tech enterprise and has established a complete production and R&D capability for the herbicide Dimethenamid-P, covering the entire industry chain from intermediates to formulations [8][15] - The company has a strong export presence, with its subsidiary Jielike operating in 79 countries, achieving over 75% of its revenue from overseas markets in 2024 [15][19] Group 5: Future Outlook and Strategic Initiatives - The company plans to continue focusing on environmentally friendly pesticide development and expand its C5 new materials product line to enhance market share and profitability [5][15] - The company aims to leverage its existing market channels and the acquisition of Jielike to penetrate emerging markets in South America, Africa, and Southeast Asia, thereby increasing sales of Dimethenamid-P [11][15]

Core Viewpoint - The company is actively advancing its projects in the green materials sector, particularly focusing on the production of specialized alcohols and cyclopentane, while also addressing financial strategies to manage costs and enhance profitability [1][2][3][4][5][6]. Project Progress - The "Annual Production of 20,000 Tons of Specialized Alcohol Series Green Materials Project" is currently in the construction phase and progressing smoothly [1]. - The "Annual Production of 12,100 Tons of Cyclopentane Series Green Materials Project" has entered trial production, with an investment of 58.31 million yuan, achieving 48.18% completion [2]. - The cyclopentane project is expected to effectively extend the company's carbon five industrial chain and improve market competitiveness [2][3]. Financial Performance - The company's revenue for 2024 reached 1.328 billion yuan, a year-on-year increase of 89.97%, primarily due to the full-year consolidation of the acquired subsidiary, Ningbo Jielike [21]. - The company is implementing cost optimization strategies, including self-supply of key raw materials like 3-pentanone, which is expected to lower production costs for its dimethyl pentyl herbicide [3][4]. Market Strategy - The company is focusing on expanding its overseas market presence, with over 75% of its revenue expected to come from international sales in 2024 [3][4]. - The acquisition of Jielike is anticipated to enhance the company's market position and sales scale in the dimethyl pentyl herbicide sector, leveraging its established channels in 79 countries [10][24]. Research and Development - The company has increased its R&D investment, with expenses totaling 45.52 million yuan in 2024, a 13.7% increase from the previous year [20]. - The company holds 58 authorized patents, including 32 invention patents, which support its competitive edge in the agricultural and new materials sectors [20][19]. Product Development - The cyclopentane production is stable, and the products are being sold in bulk, contributing to the company's revenue growth [3][22]. - The company is also exploring high-value applications for its carbon five new materials, including optical materials and pharmaceutical intermediates [16][25].